Navigation Links
Top 3 Clinical Research Organization Selects QTinno for a Phase I Drug Safety Trial
Date:11/29/2011

PRINCETON, N.J., Nov. 29, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI) a cardiovascular diagnostic solutions developer, announced today that a top 3 Clinical Research Organization (CRO) will utilize QTinno®, automated cardiac safety solution, to support a Phase I drug safety study for a biopharmaceutical sponsor.  Fully automated ECG analysis, empowered by QTinno, will be delivered at the CRO's clinical pharmacology research unit under the terms of an existing Master Services Agreement with NewCardio.

NewCardio has been asked to install QTinno at the second of this CRO's Phase 1 units, enabling them to complete  an ongoing study for their biopharmaceutical sponsor. The study is expected  to provide more refined data compared to previous analysis conducted for the cardiac safety profile of the compound.  NewCardio expects to recognize the revenue from this study during the fourth quarter of 2011.

"The recommendation by the CRO to the sponsor to utilize QTinno for this Phase 1 study is recognition that QTinno provides accuracy and timeliness, at lower cost," said Vincent Renz, NewCardio's Chief Executive Officer.  "We are excited to have achieved this milestone, and look forward to this leading to additional business with the clinical resources provider and their sponsors in the future."

NewCardio's innovative 3-D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead ECG. NewCardio's lead product, QTinno, is a software suite that provides automated, comprehensive cardiac safety analysis as defined in the ICH E14 Guidance for Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. The Company believes that QTinno, based on NewCardio's technology and approach, is the industry's most advanced, validated solution for performing high quality, cost effective automated cardiac safe
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Strategic Health Services, Inc. (SHS), a leading provider of ... agreement with QualCare, Inc., a leading provider of health plans ... marketplace.  This agreement will further QualCare,s population health management ... brings to its clients in New Jersey ... QualCare plans cover more than 800,000 member lives, with ...
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... France and SWIFTWATER, Pa., June 16 Sanofi,Pasteur, the ... donate 60 million doses of H5N1 vaccine to the ... of an H5N1 vaccine,global stockpile., "The H5N1 virus ... the world and an outbreak of pandemic influenza would ...
... Results presented at the 90th annual Endocrine Society meeting show,significant ... ... painful intercourse, ANN ARBOR, Mich, June 16 QuatRx ... 3 clinical,trial of Ophena(TM) (ospemifene tablets) to treat postmenopausal women ...
Cached Medicine Technology:Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 2Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 3Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 4Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 5Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 2Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 3Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 4
(Date:12/19/2014)... 19, 2014 Eufaula, Oklahoma, located just ... Eufaula, the state’s largest lake with more than 600 ... home to a little more than 3,000 residents, hosted ... Saturday, the 6th of December. , Featuring Santa, Christmas ... downtown Eufaula on Main Street. Narconon Arrowhead’s parade ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Potentially illness-causing E. coli ... at farmers markets, according to a new study. ... vendors from 13 farmers markets in Los Angeles and ... Out of almost 150 samples tested, 24 percent were ... salmonella, according to the researchers. Both types of ...
(Date:12/19/2014)... who have lost all their teeth have faster decreases in ... least some of their teeth, a new study says. ... early warning of increased risk of physical and mental decline ... findings don,t prove that tooth loss causes the physical or ... 60 and older. People with no remaining teeth did about ...
(Date:12/19/2014)... Kan. (PRWEB) December 19, 2014 B. ... exclusively to healthcare providers, has been retained to lead ... Estes Park Medical Center in Estes Park, Colo. The ... E. Smith has recently placed more than 900 healthcare ... (EPMC) is a 25-bed, not-for-profit critical access hospital and ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3
... American Society,of Consultant Pharmacists (ASCP) announces that Outcomes ... Medication Therapy,Management (MTM) Provider Partners. This announcement was ... 38th Annual Meeting and Exhibition,taking place in Philadelphia., ... MTM services has increased,dramatically since the coverage of ...
... years that psychological trauma that results in post-traumatic ... a person responds to stress. Now, Cornell researchers ... life-threatening accidents and other such traumas may result ... develop a clinical disorder., "The findings suggest that ...
... JAPAN, November 20, 2007 Bristol-Myers Squibb Company (NYSE: ... the U.S. Food and Drug Administration (FDA) approved the ... add-on, treatment to antidepressant therapy (ADT) in adults with ... medication approved by the FDA as add-on treatment for ...
... 20 Crdentia Corp. (OTC Bulletin,Board: CRDT), a ... Ms. Penny Kirsch to Vice President of Human ... Manager,for Crdentia and will continue to report to ... be responsible for all human resources operations for ...
... Nov. 20 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a ... and drug delivery products, today,announced that President and CEO ... Markets Fourth Annual Healthcare Conference at the Palace,Hotel in ... 1:30 p.m. EST. Lazard Capital Markets will host ...
... Molecular Imaging Zone, FORT LAUDERDALE, Fla., Nov. ... IMDS) a pioneer in laser,optical breast cancer imaging ... cases imaged with optical computed tomography,technologies at RSNA ... 28. A CT,Laser Mammography (CTLM(R)) system and clinical ...
Cached Medicine News:Health News:Outcomes Pharmaceutical Health Care(r) Becomes an ASCP MTM Provider Partner 2Health News:FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD 2Health News:FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD 3Health News:FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD 4Health News:FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD 5Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 2Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 3Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 2Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 3
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
The ACMI™ Operative Laparoscopy System is designed for single- and dual-incision CO2 laser procedures and is used with 45cm laparoscopic instruments....
The edge-to-edge clarity of the laparoscopes provides excellent image definition.Even small structures are easily recognized due to the optimal depth of focus. The outstanding optical quality provide...
Stryker bariatric laparoscopes set the standard in picture quality....
Medicine Products: